CoChat

Pharmacologic Options for the Treatment of Sarcopenia

Morley, John E. · 2016 · Calcified Tissue International

The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.

Abstract

Sarcopenia is now clinically defined as a loss of muscle mass coupled with functional deterioration (either walking speed or distance or grip strength). Based on the FRAX studies suggesting that the questions without bone mineral density can be used to screen for osteoporosis, there is now a valid simple questionnaire to screen for sarcopenia, i.e., the SARC-F. Numerous factors have been implicated in the pathophysiology of sarcopenia. These include genetic factors, mitochondrial defects, decreased anabolic hormones (e.g., testosterone, vitamin D, growth hormone and insulin growth hormone-1), inflammatory cytokine excess, insulin resistance, decreased protein intake and activity, poor blood flow to muscle and deficiency of growth derived factor-11. Over the last decade, there has been a remarkable increase in our understanding of the molecular biology of muscle, resulting in a marked increase in potential future targets for the treatment of sarcopenia. At present, resistance exercise, protein supplementation, and vitamin D have been established as the basic treatment of sarcopenia. High-dose testosterone increases muscle power and function, but has a number of potentially limiting side effects. Other drugs in clinical development include selective androgen receptor molecules, ghrelin agonists, myostatin antibodies, activin IIR antagonists, angiotensin converting enzyme inhibitors, beta antagonists, and fast skeletal muscle troponin activators. As sarcopenia is a major predictor of frailty, hip fracture, disability, and mortality in older persons, the development of drugs to treat it is eagerly awaited.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00223-015-0022-5

Cites

161 of 161 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 4

  1. Rolland Y, Lauwers-Cances V, Crostini C, Abellan van Kan G, Janssen I, Morley JE, Vellas B (2009) Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women. EPIDOS Study 89:1895–1900
  2. Kim MJ, Morley JE (2005) The hormonal fountains of youth: myth or reality? J Endocrinol Invest 28(11):5–14
  3. Temel J, Bondarde S, Jain M, Yun Y, Duus E, Allen S et al (2013) Efficacy and safety results from a phase II study of anamorelin HC21, a ghrelin receptor agonist, in NSCLC patients. J Cachexia Sarcopenia Muscle 4:334
  4. Malik F (2013) Fast skeletal muscle troponin activators and their application to disease-preclinical characterization. In: Abstracts, 7th Cachexia Conference, Kobe. p 50

Cited by

See all 225

Metadata

Authors
Morley, J. E.
Affiliations
Saint Louis University (US)
Corresponding author
Morley, John E.
Venue
Calcified Tissue International
Published
2015-06-23
Volume
98
Issue
4
Pages
319-333
ISSN
  • 0171-967X (ISSN-L)
  • 1432-0827
OpenAlex
W819537267
Cited by
225
References
161
Citations by year
2026: 10 · 2025: 18 · 2024: 16 · 2023: 15 · 2022: 20 · 2021: 23 · 2020: 20 · 2019: 23 · 2018: 29 · 2017: 27 · 2016: 18 · 2015: 6
FWCI
3.27
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Calcified Tissue International (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
sarcopenia, sarcopenia treatment, muscle mass loss, muscle function, testosterone replacement therapy, selective androgen receptor modulators, ghrelin agonists, ACE inhibitors, beta-blockers, protein supplementation, vitamin D, resistance training, frailty, older adults
MeSH terms
Humans, Drug Discovery, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.